MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study

Bibliographic Details
Title: MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study
Authors: Aurora Zanghì, Virginia Manuti, Gaetano Serviddio, Emanuele D’Amico, Carlo Avolio
Source: Frontiers in Immunology, Vol 14 (2023)
Publisher Information: Frontiers Media S.A., 2023.
Publication Year: 2023
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: multiple sclerosis, cerebrospinal fluid (CSF), oligoclonal bands (OCBs), biomarkers, MicroRNAs, early disease biomarkers, Immunologic diseases. Allergy, RC581-607
More Details: BackgroundCirculating microRNAs (MiRNAs) have been investigated for their role in fine-tuning the adaptive immune response to inflammatory factors and in Multiple Sclerosis (MS). They have been investigated as possible biomarkers for the diagnosis and prognosis of the disease.MethodsA cross sectional study conducted at the MS centre of Foggia, Italy. We enrolled patients with (1) an age between 18 and 55 years, (2) a definitive diagnosis of relapsing remitting MS (RRMS) as per the revised McDonald criteria, and (3) naïve to any disease modifying therapy (DMTs), as well as (4) patients with other neurological disorders (OND). The aim of the study was to compare the levels of expression of miRNA 21-5p, miRNA 106a-5p, miRNA 146a-5p, and miRNA223-3p in cell-free cerebrospinal fluid (CSF) in RRMS patients and OND. Investigated MiRNAs were extracted, retrotranscribed, and then assessed by real-time polymerase chain reaction assay (q-PCR). A receiver-operator characteristic (ROC) curve was used to test MiRNAs as a biomarker for diagnosing MS. A linear regression analysis was done to find any association with disease characteristics at the time of diagnosis.ResultsA total cohort of 70 subjects (70% women) was analyzed. Out of them, 35 had a RRMS diagnosis. MiRNA 106a-5p (7.8 ± 3.8 vs 1.3 ± 0.9, p=0.03) had higher levels in RRMS patients when compared to OND. The ROC curve indicated that MiRNA 106a-5p could be considered as a disease biomarker with an area under the curve of 0.812 (p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-3224
Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1226130/full; https://doaj.org/toc/1664-3224
DOI: 10.3389/fimmu.2023.1226130
Access URL: https://doaj.org/article/65ff34efb7354a93a001897480b39406
Accession Number: edsdoj.65ff34efb7354a93a001897480b39406
Database: Directory of Open Access Journals
More Details
ISSN:16643224
DOI:10.3389/fimmu.2023.1226130
Published in:Frontiers in Immunology
Language:English